Home / Pharma Healthcare / Global Cancer Pain Therapeutics Market Research Report 2019

Global Cancer Pain Therapeutics Market Research Report 2019

  • Id : RNR-264420
  • Category : Pharma Healthcare
  • Publish Date : Mar-19
  • Publisher : Research-N-Reports
  • Pages : 123
  • Format : PDF
License Type

Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostic procedures or from skin, nerve, and the other changes caused by a hormone imbalance or immune response.
Factors such as the unmet medical needs of patients drive the market growth during the forecast period. Currently, the drugs that are available for reducing pains associated with cancer have a prolonged duration of action and are characterized by undesirable effects like sedation and respiratory depression. Consequently, this presents an opportunity for the vendors to bring in therapies with fewer side effects and a better efficacy parameter.

The global Cancer Pain Therapeutics market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Cancer Pain Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Cancer Pain Therapeutics market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
BioDelivery Science
ProStrakan Group
Teva pharmaceuticals
Grunenthal Group
GW Pharmaceuticals
Meda Pharmaceuticals
WEX Pharmaceuticals

Segment by Regions
North America

Segment by Type
Non-Steroidal Anti-Inflammatory Drugs

Segment by Application
Paracetamol Treatment-Related Immunotherapy
Hormone Therapy